From the Research
Eliquis (apixaban) is not typically prescribed specifically for Factor V Leiden mutation alone, and the decision to use anticoagulation should be determined by a healthcare provider based on a patient's complete medical history. If anticoagulation is needed, the standard Eliquis dose is typically 5 mg twice daily, though some patients may receive 2.5 mg twice daily if they meet certain criteria (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) 1. The most recent and highest quality study, published in 2025, found that apixaban was associated with a significantly reduced incidence of anticoagulation-related ED admission compared to warfarin in patients with severe renal impairment 1. Key points to consider when determining the Eliquis dose for a patient with Factor V Leiden include:
- The patient's clotting history and risk factors
- The presence of other genetic mutations or medical conditions that may affect clotting risk
- The patient's renal function and potential need for dose adjustment
- The potential benefits and risks of anticoagulation therapy, including the risk of bleeding and recurrent venous thromboembolism (VTE) 2, 1. It is essential to weigh these factors and consider the latest evidence when making a decision about Eliquis dosing for a patient with Factor V Leiden.